Company Overview of TauRx Pharmaceuticals Ltd.
TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases. Its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.
3, Shenton Way
Founded in 2002
Key Executives for TauRx Pharmaceuticals Ltd.
Co-Founder, Chairman and Chief Executive Officer
Chief Operating Officer and Chief Business Officer
Managing Director and Director
Compensation as of Fiscal Year 2017.
TauRx Pharmaceuticals Ltd. Key Developments
TauRx Pharmaceuticals Ltd. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017
Mar 11 17
TauRx Pharmaceuticals Ltd. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017 . Venue: Grand Hyatt Tokyo, Tokyo, Japan. Speakers: Timothy Earle, Chief Operating Officer and Chief Business Officer.
TauRx Therapeutics Ltd Reports First Phase 3 Results for LMTX
Jul 27 16
TauRx Therapeutics Ltd. announced Phase 3 clinical trial results that show treatment with LMTX®, the company's novel tau aggregation inhibitor, had a marked beneficial effect on key measures of Alzheimer's disease in patients with mild or moderate forms of the disease. While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX® as their only Alzheimer's disease medication. These three key measures comprised a cognitive assessment (ADAS-Cog), a functional assessment (ADCS-ADL) and an assessment of the level of brain atrophy (lateral ventricular volume, LVV, as measured by MRI). An abstract of the results will be presented during an open session at the 2016 Alzheimer's Association International Conference (AAIC) in Toronto, Canada this afternoon by Dr. Serge Gauthier, CM, MD, FRCPC, Director of the Alzheimer's Disease Research Unit, McGill University, Canada. The same efficacy findings were not seen in study patients who took LMTX® in combination with other standard Alzheimer's treatments. Since these patients formed the substantial majority of those recruited to the trial, the treatment benefits seen in those taking LMTX® as monotherapy could not be seen when all patients taking LMTX® were pooled in the primary analysis model. Although this prevented the study from achieving an overall statistical significance in the pooled analysis, the primary analysis model showed a highly significant effect of treatment in the patients taking LMTX® as monotherapy. This treatment benefit was confirmed in a prespecified supportive analysis of all of the study's primary and secondary outcomes. This is the first treatment in which a clinical effect has been supported by evidence in delay of progression in brain atrophy shown by MRI scans. An initial analysis of data from the second of TauRx's two Phase 3 trials in Alzheimer's disease, study TRx-237-005 undertaken in 800 patients with the mild form of the disease, confirms the findings of study TRx-237-015 and supports the potential of LMTX® as monotherapy. The results from this study are expected to be published and presented later in 2016.
TauRx Pharmaceuticals Ltd. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 08:30 AM
Feb 17 16
TauRx Pharmaceuticals Ltd. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 08:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, Room 508, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|